Circular RNA circMDM2 accelerates the glycolysis of oral squamous cell carcinoma by targeting miR-532-3p/HK2

被引:26
|
作者
Zheng, Zhao [1 ]
Ma, Xiaozhou [1 ]
Li, Hongfa [1 ]
机构
[1] Tianjin Med Univ, Sch & Hosp Stomatol, Tianjin 300070, Peoples R China
关键词
circMDM2; glycolysis; HK2; oral squamous cell carcinoma; EPIGENETIC REGULATION; CANCER PROGRESSION; COLORECTAL-CANCER; PROLIFERATION; DIFFERENTIATION; GROWTH;
D O I
10.1111/jcmm.15380
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Circular RNAs (circRNAs) function as an essential regulator in the progression of oral squamous cell carcinoma (OSCC). However, the potential roles and mechanism of circRNAs in OSCC are still elusive. Here, this research investigates the roles and molecular mechanism of novel circRNA (circMDM2) in OSCC progression. Clinically, circMDM2 was overexpressed in OSCC tissue and cells, and the overexpression served as a poor prognostic factor for OSCC patients. Functionally, cellular experiments confirmed that circMDM2 accelerated OSCC cell proliferation and glycolysis in vitro and circMDM2 knockdown repressed the tumour growth in vivo. Mechanistically, circMDM2 sponged miR-532-3p to promote the hexokinase 2 (HK2), forming the circMDM2/miR-532-3p/HK2 axis. In conclusion, these findings demonstrated that circMDM2/miR-532-3p/HK2 axis promotes the proliferation and glycolysis of OSCC, rendering a potential diagnostic biomarker and prospective therapeutic target for OSCC.
引用
收藏
页码:7531 / 7537
页数:7
相关论文
共 50 条
  • [31] Circular RNA circCUL3 Accelerates the Warburg Effect Progression of Gastric Cancer through Regulating the STAT3/HK2 Axis
    Pu, Zhichen
    Xu, Maodi
    Yuan, Xiaolong
    Xie, Haitang
    Zhao, Jun
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2020, 22 : 310 - 318
  • [32] Curcumin inhibits esophageal squamous cell carcinoma progression through down-regulating the circNRIP1/miR-532-3p/AKT pathway
    Luo, Tianxia
    Guan, Hongya
    Liu, Jia
    Wang, Jiang
    Zhang, Yueli
    ENVIRONMENTAL TOXICOLOGY, 2023, 38 (11) : 2705 - 2716
  • [33] Circular RNA hsa_circ_0013958 Functions as an Oncogenic Gene Through Modulating miR-532-3p/WEE1 Axis in Hepatocellular Carcinoma
    Ma, Tao
    Ma, Yue
    Du, Yongjun
    Wei, Zhongheng
    Wang, Jianchu
    Jun, Yufu
    Xiao, Fenqiang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] Long noncoding RNA CASC7 is a novel regulator of glycolysis in oesophageal cancer via a miR-143-3p-mediated HK2 signalling pathway
    Wei Sun
    Dao Wang
    Yukun Zu
    Yu Deng
    Cell Death Discovery, 8
  • [35] Long noncoding RNA CASC7 is a novel regulator of glycolysis in oesophageal cancer via a miR-143-3p-mediated HK2 signalling pathway
    Sun, Wei
    Wang, Dao
    Zu, Yukun
    Deng, Yu
    CELL DEATH DISCOVERY, 2022, 8 (01)
  • [36] Long Non-Coding RNA LINC01929 Accelerates Progression of Oral Squamous Cell Carcinoma by Targeting the miR-137-3p/FOXC1 Axis
    Che, Hongze
    Che, Yanhai
    Zhang, Zhimin
    Lu, Qing
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] Long non-coding RNA UCA1 modulates the glycolysis of cervical cancer cells by miR-493-5p/HK2
    Wu, Fengli
    Zhou, Dan
    Cui, Ying
    Shen, Guihua
    Li, Ye
    Wei, Fenghua
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (08): : 3943 - 3951
  • [38] Low expression of miR-532-3p contributes to cerebral ischemia/reperfusion oxidative stress injury by directly targeting NOX2
    Mao, Li
    Zuo, Mei-Ling
    Wang, Ai-Ping
    Tian, Ying
    Dong, Li-Chen
    Li, Tao-Ming
    Kuang, Da-Bin
    Song, Gui-Lin
    Yang, Zhong-Bao
    MOLECULAR MEDICINE REPORTS, 2020, 22 (03) : 2415 - 2423
  • [39] Circ-PGC increases the expression of FOXR2 by targeting miR-532-3p to promote the development of non-small cell lung cancer
    Xia, Daokui
    Chen, Zhen
    Liu, Quan
    CELL CYCLE, 2021, 20 (21) : 2195 - 2209
  • [40] RETRACTION: Circular RNA hsa_circ_0013958 functions as an oncogenic gene through modulating miR-532-3p/WEE1 axis in hepatocellular carcinoma
    Ma, T.
    Ma, Y.
    Du, Y.
    Wei, Z.
    Wang, J.
    Jun, Y.
    Xiao, F.
    FRONTIERS IN ONCOLOGY, 2024, 14